🇺🇸 FDA

Company profile · Sponsor

Kalvista

Kalvista Pharmaceuticals (Ireland) Limited

KALV · NYSE pharma FRAMINGHAM, MA, GB
Pipeline
8
Drugs
1
Patents
8

Quick answer

Kalvista (KALV) is a pharma company. headquartered in FRAMINGHAM, MA, GB. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker KALV
Exchange NYSE
Company type pharma
Headquarters FRAMINGHAM, MA, GB
SEC CIK 0001348911

Pipeline (8)

Search pipeline →

  1. KVD900 150 mg

    Kalvista

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  2. KVD900 600 mg

    Kalvista

    Hereditary Angioedema

    phase 3 small molecule active

    2 trials

  3. Placebo

    Kalvista

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  4. KVD001 Injection

    Kalvista

    Diabetic Macular Edema

    phase 2 small molecule completed

    2 trials

  5. KVD824

    Kalvista

    Angioedema, Hereditary, Types I and II

    phase 2 small molecule terminated

    1 trial

  6. KVD900

    Kalvista

    Hereditary Angioedema

    phase 2 small molecule completed

    2 trials

  7. KVD824

    Kalvista

    Hereditary Angioedema

    phase 1 small molecule completed

    1 trial

  8. KVD824 Prototype 1 modified-release tablet

    Kalvista

    Hereditary Angioedema

    phase 1 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. sebetralstat

    EKTERLY

    ORAL approved

    B06AC08

Patents (8)

Search patents →

  1. US 11739068

    Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11613527

    Enzyme inhibitors

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11584735

    Solid forms of a plasma kallikrein inhibitor and salts thereof

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11242333

    Inhibitors of plasma kallikrein

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11234939

    Dosage forms comprising a plasma kallikrein inhibitor

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11230537

    Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11198691

    N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11180484

    Pyrazole derivatives as plasma kallikrein inhibitors

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Kalvista?

Kalvista (KALV) is a pharma company. headquartered in FRAMINGHAM, MA, GB. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Kalvista sponsor?

We track 8 ClinicalTrials.gov-linked programs for Kalvista, including KVD900 150 mg and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Kalvista company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.